Kenvue Inc. (NYSE:KVUE) Shares Sold by First Trust Advisors LP

First Trust Advisors LP reduced its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 21.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,207,619 shares of the company's stock after selling 325,028 shares during the quarter. First Trust Advisors LP owned about 0.06% of Kenvue worth $25,783,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Grove Bank & Trust lifted its stake in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in Kenvue in the 4th quarter worth $29,000. SRS Capital Advisors Inc. lifted its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

NYSE:KVUE traded up $0.19 during trading hours on Thursday, hitting $23.79. 4,030,756 shares of the stock were exchanged, compared to its average volume of 17,005,961. The company has a market cap of $45.64 billion, a P/E ratio of 44.97, a P/E/G ratio of 2.62 and a beta of 1.02. The firm's fifty day moving average price is $23.07 and its 200 day moving average price is $22.47. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 154.72%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Citigroup upped their target price on Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Barclays cut their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Monday, April 14th. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Finally, Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.